UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals on Pending Acquisitions of Optimer and Trius
October 09, 2013 at 11:51 AM EDT
In a report published Wednesday, Mizuho Securities analyst Mario Corso upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST ) from Neutral to Buy, and raised the price target from $50.00 to $77.00. In the report, Mizuho Securities noted, “We are upgrading our rating on CBST shares to Buy from Neutral
